ACC: J&J, Bayer's Xarelto scores trial win in artery disease by Kyle Blankenship Saturday, March 28, 2020 Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.
Biogen, Bayer rogue staffers; Kaletra and more—FiercePharmaAsia by Angus Liu Friday, March 20, 2020 Biogen and Bayer deal with coronavirus rule-breakers in China. AbbVie's Kaletra fails COVID-19 study. Fosun licenses BioNTech's coronavirus vaccine.
Bayer donates chloroquine to fight COVID-19 by Eric Sagonowsky Wednesday, March 18, 2020 Bayer is getting ready to donate a potential COVID-19 treatment to the U.S. government, Axios reports.
Bayer fires China quarantine-breaker by Angus Liu Tuesday, March 17, 2020 The incident comes after a video of the staffer went viral—and as China works to control coronavirus cases imported by international travelers.
Pharma sales reps stay home, use digital tools to contact docs by Beth Snyder Bulik Tuesday, March 17, 2020 As COVID-19 spreads, pharma's forcing sales reps to stay at home, subbing digital tools and virtual meetings for face-to-face physician visits.
AHA halts Bayer's pharmacy displays of 'baby aspirin' by Phil Galewitz, Kaiser Health News Tuesday, March 10, 2020 The AHA told Bayer to take down displays of "baby aspirin" because they could falsely suggest the med could reduce heart attack risk.
Bayer and MassBio teach startups regulatory ins and outs by Beth Snyder Bulik Wednesday, March 11, 2020 Bayer and the Massachusetts Biotechnology Council this week open a regulatory best practice center for biotech and digital health startups.
Bayer yields to shareholder request for M&A rules review by Angus Liu Thursday, February 27, 2020 Ahead of its annual shareholder meeting, Bayer agreed to a corporate governance expert's request for a review of its metrics for evaluating M&A.
Bayer picks an unconventional board chair amid Roundup woes by Arlene Weintraub Wednesday, February 26, 2020 A pharma outsider is taking over as Bayer's chairman as it navigates troubles ranging from Roundup suits to challenges facing its new cancer drugs.
Picture this: Bayer's living murals flag hidden heart risks by Beth Snyder Bulik Thursday, February 13, 2020 The latest campaign for Bayer Aspirin features an artist painting heart attack survivors scenes to illustrate the hidden risks of heart disease.
